Urifast

Quick links to important sections

Urifast

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urifast

Quick Facts

Property Description
Active ingredient Nitrofurantoin
Form Capsule, Tablet, Oral suspension
Pharmacological class Antibacterial agent, Nitrofuran derivative
Common use (General) Combating lower urinary tract infections
Origin Synthetic compound

What Type of Medicine is Urifast? (Identity, Class, and Origin)

Urifast is a synthetic antibacterial agent whose active substance is Nitrofurantoin, officially classified as a nitrofuran derivative. This medicine belongs to the broader pharmacological group of anti-infectives and is distinguished by its focused action against lower urinary tract pathogens, a role clinically recognized for its long-term efficacy. The compound has been used successfully for over 60 years in treating lower urinary tract infections without notable increase in antibiotic resistance. This long-standing efficacy confirms its established importance in clinical practice, having been included on the World Health Organization's List of Essential Medicines since 1979.

Composition and Available Pharmaceutical Preparations

The high-level composition of Urifast relies exclusively on the Nitrofurantoin molecule, classifying it as a single active ingredient product, typically administered orally. The formulation is often prepared as macrocrystals or a combination of monohydrate/macrocrystals, a specialized process designed to enhance patient tolerance and optimize the concentration profile in the urine. Urifast is manufactured in several distinct dosage forms, including the standard capsule, tablet, and oral suspension, combining the active ingredient with necessary pharmaceutical excipients for stable and effective delivery.

General Purpose and Fundamental Action

The fundamental purpose of Urifast is to combat microbial proliferation by exerting a potent and localized antibacterial effect, making it a primary choice for managing uncomplicated lower urinary tract infections. Its unique mechanism is supported by pharmacological studies demonstrating that the medicine is processed by bacterial enzymes, which generates highly reactive intermediates inside the cell. These intermediates simultaneously target and disrupt multiple vital bacterial systems, including DNA, RNA, and enzyme pathways. This mechanism means the drug functions as both a bacteriostatic agent (slowing growth) and a bactericidal agent (actively eliminating the bacteria).

Regulatory References

  1. World Health Organization's List of Essential Medicines
  2. [WHO eEML]

What side effects are possible with Urifast?

Possible side effects and safety information

Official regulatory documentation classifies the possible side effects of Urifast (Nitrofurantoin) by frequency and the body system affected. The most common adverse reactions are generally related to the Gastrointestinal System, including nausea, vomiting, anorexia (loss of appetite), diarrhea, and flatulence. The medicine may also impart a non-pathological yellow or brown color to the urine, an expected effect noted in labeling.

Serious Adverse Reactions and Systemic Toxicities

The safety profile includes rare but serious reactions affecting vital organ systems. These are primarily categorized as Hepatotoxicity (liver damage), which encompasses hepatitis, cholestatic jaundice, and chronic active hepatitis; and Pulmonary Reactions, which range from acute reactions (often occurring in the first week of treatment) to chronic, potentially fatal conditions like pulmonary fibrosis, generally associated with exposure lasting six months or longer. Peripheral Neuropathy, which can be severe or irreversible, is also a serious reaction listed in post-marketing reports.

Population-Specific Safety Constraints

The medicine is subject to explicit regulatory contraindications concerning specific patient populations. It is contraindicated in patients with significant renal impairment (kidney function below a creatinine clearance of 60 mL/min). Furthermore, it is contraindicated in pregnant patients at term (38–42 weeks gestation) and in infants under one month of age due to the potential risk of hemolytic anemia in the neonate. Individuals with G6PD deficiency are also susceptible to hemolytic anemia, which is a known regulatory safety constraint.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Urifast (Nitrofurantoin) overdose documents the expected clinical presentation and the required emergency actions.

Acute overdosage is formally characterized by signs of gastric irritation, typically manifesting as nausea and vomiting. However, the primary concern with overexposure is the potential for severe or life-threatening outcomes due to the exaggeration of known systemic toxicities. These serious manifestations include the risk of irreversible peripheral neuropathy and potentially fatal hepatic or pulmonary reactions.

Management for suspected overdose is strictly symptomatic and supportive, as no specific antidote is known. Officially described procedures may involve interventions such as gastric lavage or emesis induction, alongside maintaining high fluid intake to promote excretion. Specialized monitoring, including liver function and blood tests, may be required.

Immediate medical help must be sought in all cases of suspected overdose. Regulatory documents mandate calling emergency services or the Poison Help line if the affected individual has collapsed, had a seizure, or is experiencing trouble breathing. The risk of severe toxicity is noted to be significantly increased in individuals with impaired renal function (creatinine clearance less than 60 mL/minute) due to reduced drug clearance, and haemodialysis may be considered to aid drug removal in such cases.

Therapeutic Uses of Urifast

Main Uses of Urifast

Urifast is an antibacterial medication specifically formulated to treat acute, uncomplicated urinary tract infections (UTIs). Its primary therapeutic use is the management of cystitis, which is an infection of the bladder.

The medication is effective against a variety of Gram-positive and Gram-negative bacteria that commonly reside in the urinary tract. It works by interfering with the bacterial cell's ability to produce energy and synthesize vital proteins, DNA, and cell walls, thereby inhibiting the growth and spread of the infection.

Key Benefits and Clinical Applications

  • Targeted Action: The active ingredient in Urifast is rapidly absorbed and concentrated in the urine, allowing the medication to act directly at the site of the infection.
  • Broad Spectrum: It is active against common uropathogens, including Escherichia coli, which is the most frequent cause of bladder infections.
  • Symptomatic Relief: By eliminating the underlying bacterial infection, the medication helps resolve the physical discomfort associated with cystitis, such as burning sensations during urination, increased frequency of urination, and pelvic pressure.
  • Minimal Impact on Systemic Flora: Due to its rapid excretion and specific concentration in the urinary tract, it has a lower tendency to disrupt the natural bacterial balance in other parts of the body compared to some broad-spectrum antibiotics.

Eligibility and Restrictions for Use

Urifast (usually a brand name for Nitrofurantoin) is commonly prescribed to treat and prevent urinary tract infections (UTIs).

However, it is not suitable for everyone. A healthcare provider must assess a patient's medical history before prescribing Urifast, as it can be contraindicated in certain populations.


Who Can Use Urifast?

Generally, Urifast is safe and effective for:

  • Adults and children over the age of three months with uncomplicated UTIs.
  • Individuals requiring long-term prophylaxis (prevention) of recurrent UTIs.

Who Cannot Use Urifast?

The medication should be avoided by or used with extreme caution in patients with the following conditions:

Condition / Population Rationale for Caution
Severe kidney impairment Risk of drug accumulation and reduced effectiveness.
G6PD deficiency Risk of hemolytic anemia (a type of blood disorder).
Pregnant women (near term) Risk of hemolytic anemia in the newborn.
Infants (under three months old) Risk of hemolytic anemia due to immature enzyme systems.
Known allergy to nitrofurantoin Risk of severe hypersensitivity reactions.

Patients with lung disease or liver disease may also require closer monitoring during treatment. Always consult a healthcare professional for a personalized assessment.

What should I know about interactions with other medicines?

The interaction profile for Urifast, whose active ingredient is Nitrofurantoin, is defined by documented effects on the drug’s absorption and renal elimination, as specified in official regulatory prescribing information.


Interacting Medicines and Substances

Substance Class Specific Interacting Medicine Official Interaction Outcome
Uricosuric Agents Probenecid, Sulfinpyrazone Reduce Urifast's renal secretion, leading to lower urinary concentrations (reduced efficacy) and increased blood plasma concentrations (potential for increased systemic exposure).
Gastrointestinal Modifiers Antacids (containing magnesium trisilicate) Decrease the rate and total extent of Urifast absorption from the digestive tract.
Nutritional Substance Food or Milk Significantly enhances the oral absorption and bioavailability of Urifast.

Interaction-Related Restrictions

Regulatory documents state that co-administration with medicines that inhibit renal clearance, such as Probenecid and Sulfinpyrazone, is restricted as it compromises the goal of achieving therapeutic drug concentrations in the urinary tract. The risk of increased systemic exposure and potential toxicity from these interactions is specifically noted to be higher in patients with pre-existing impaired renal function (creatinine clearance less than 60 mL/min). In vitro data shows an antagonism between Urifast and quinolone antimicrobial agents, although regulatory labeling notes that the clinical significance of this finding is unknown.

Mechanism of Action

How Urifast Works: Mechanism of Action

Urifast's mechanism involves a localized, multi-target attack against essential bacterial systems rather than a single enzymatic inhibition.


Enzyme-Dependent Intracellular Activation

The core mechanism involves reductive activation, where the drug requires the bacteria's own nitroreductase enzymes (NfsA and NfsB) to convert it into a chemically reactive form. By utilizing the pathogen's own metabolic machinery for activation, this process generates nitro-anion free radicals and other toxic reactive intermediates, initiating the multi-target damage cascade within the cytosol.


Simultaneous Disruption of Macromolecular Synthesis

Once activated, these reactive species attack and covalently bind to multiple vital components, including bacterial DNA, RNA, ribosomal proteins, and metabolic enzymes (e.g., in the Citric Acid Cycle). This concurrent damage halts replication, protein production, and energy generation, leading to the suppression of microbial function. This multi-target insult results in both bacteriostasis (growth suppression) and bactericidal action (cell elimination).


Concentration-Constrained Localized Action

The activity of this mechanism is highly dependent on achieving and maintaining very high drug concentrations exclusively within the urine. This physiological constraint ensures that the drug maintains a high level of anti-microbial activity locally, resulting in a high level of localized microbial suppression in the lower urinary tract environment where the high concentration is sustained.

Dosage and Administration Information

How to Use Urifast

Urifast is a medicine used to manage urinary tract infections. The administration of this medicine is oral and is available in several forms, including immediate-release capsules, tablets, and an oral suspension. Proper usage involves adherence to specific dosing schedules and administration conditions.


Usage Protocols

Instruction Domain Administration Principle
Route of Administration Exclusively oral.
Contextual Intake Must be consumed with food or milk to maximize absorption and reduce gastrointestinal effects.
Dosing Frequency For acute treatment, the immediate-release form is typically taken four times daily (Q.I.D.). For long-term prevention, the regimen is usually once daily (Q.D.), often at bedtime.
Treatment Duration The standard course for acute uncomplicated use is generally seven days.

Administration Details and Constraints

Standard adult dosing ranges from 50 mg to 100 mg per dose, depending on the indication. For pediatric patients over one month of age, dosing is determined based on body weight. When using the oral suspension, the liquid must be vigorously shaken before measuring the dose. Usage is generally restricted in individuals with severely reduced kidney function, such as a creatinine clearance less than 60 mL/min.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical trials involving Urifast (nitrofurantoin) focus on its use for the treatment and prevention of uncomplicated urinary tract infections (UTIs), often caused by susceptible strains of bacteria such as Escherichia coli.

Clinical Trial Outcomes

Randomized controlled trials (RCTs) have been conducted to evaluate the drug’s effectiveness in achieving clinical and microbiological resolution of UTIs, which includes the complete resolution of signs and symptoms and a significant reduction in the causative pathogen count. The primary outcomes evaluated in these trials primarily measured patient-reported symptoms, such as painful urination (dysuria), urgency, and frequency, over a typical 7-day treatment course.

  • Resolution Rates: Studies have reported varied rates of clinical resolution at follow-up, typically assessed at 7 to 28 days post-treatment. Composite endpoints requiring both symptom clearance and microbiological success have been used for evaluation.
  • Prophylactic Use: Research has also explored the drug's role in the long-term prevention (prophylaxis) of recurrent UTIs, comparing its use to other prophylactic agents or placebo.

Tolerability Data Summary

Research has reviewed the drug's tolerability, with common events reported across clinical trials including gastrointestinal effects (nausea, vomiting, diarrhea) and headaches. Due to its mechanism, studies have specifically reviewed the incidence of pulmonary and hepatic adverse events, especially in cases of long-term administration. Studies have also been conducted to observe the drug's tolerability profile in specific patient subgroups, such as those with pre-existing kidney conditions.

Key Studies & References

  1. Hepatotoxicity associated with long-term nitrofurantoin use: a case report and review of the literature

Frequently Asked Questions (FAQ)

Common questions about Urifast (FAQ)


Q: How quickly does Urifast usually start working for a UTI?

A: Clinical experience, supported by research, suggests that symptoms of a bladder infection may begin to improve within the first 48 hours of starting treatment with Urifast. Completing the full prescribed course is important, even if you notice symptom improvement early.


Q: What are the most common side effects reported with Urifast?

A: According to official product information, the most common side effects reported with Urifast are generally related to the gastrointestinal system. These include nausea, vomiting, diarrhea, loss of appetite (anorexia), and headache.


Q: Can Urifast cause stomach upset or nausea?

A: Gastrointestinal upset, including nausea and vomiting, is among the most frequently reported side effects in official documents. Official product information suggests taking the medicine with food or milk, as this may help maximize absorption and reduce the chance of experiencing these gastrointestinal effects.


Q: Are there any specific foods to avoid when using Urifast?

A: While there are no major food interactions listed that reduce the drug's effectiveness, some common recommendations for managing UTI symptoms include reducing the intake of acidic foods, spicy foods, and caffeine. This is related to managing general bladder irritation that is associated with a urinary tract infection.


Q: What if the UTI symptoms don't improve after a few days on Urifast?

A: If symptoms do not begin to improve, or if they worsen during the course of treatment, official guidelines indicate that this situation warrants reevaluation by a healthcare professional.


Q: Do I have to finish the whole course of Urifast even if I feel better?

A: Regulatory documents emphasize that completing the full prescribed course of treatment is important to ensure the infection is fully cleared. This helps prevent the infection from returning or potentially becoming more difficult to treat.


Q: Is it common to feel tired after taking Urifast?

A: Drowsiness and weakness are among the reported side effects of this medicine, according to official labeling. These central nervous system (CNS) effects may contribute to a feeling of tiredness in some patients.


Q: Is it safe to drink coffee while taking Urifast?

A: There is no direct drug-drug interaction listed between Urifast and coffee. However, caffeine is a known bladder irritant that may worsen existing urinary tract infection symptoms, so individuals may wish to consider limiting caffeine intake while treating a UTI.


Q: What are the signs that Urifast is starting to work?

A: Official information indicates that signs of the medication beginning to work include the gradual resolution of primary UTI symptoms. These symptoms include a decrease in painful urination (dysuria), urinary urgency, and frequency, often starting within 48 hours.


Q: Is Urifast linked to any rare, but serious side effects?

A: Yes, official regulatory labeling includes warnings about rare but serious potential reactions that can affect major organ systems. These include liver damage (hepatotoxicity), acute or chronic lung reactions (pulmonary toxicity), and nerve damage (peripheral neuropathy).


Q: What kind of research has been done on the long-term safety of Urifast?

A: Regulatory documents and clinical studies specifically review the safety of long-term use for this medication. They note that the rare but serious adverse events, such as chronic lung disease, are typically associated with extended, continuous exposure lasting six months or longer.


Q: Why is Urifast sometimes prescribed to prevent UTIs?

A: Urifast is used for the long-term prevention (prophylaxis) of recurrent UTIs because its mechanism of action is highly localized. It achieves and maintains very high drug concentrations almost exclusively within the urine, which helps suppress microbial growth in the lower urinary system.


Q: Does Urifast interact with alcohol?

A: Regulatory information suggests caution regarding alcohol intake while using this medicine. Alcohol may increase the risk of certain side effects, such as nausea and headache, and may worsen the symptoms associated with the underlying urinary tract infection.


Q: Is it okay to take Urifast with milk or dairy products?

A: Official labeling suggests taking this medicine with food or milk, as this may help maximize the absorption of the drug into the body. Taking it with milk may also help reduce the chance of experiencing gastrointestinal side effects.


Q: Why do some people experience headaches when taking Urifast?

A: Headache is a commonly reported adverse reaction listed in official product information. It is classified as a central nervous system (CNS) effect that occurs in some patients, although the exact reason for the headache is not typically specified.


Q: How long does Urifast stay in your system after the last dose?

A: Official pharmacological data indicates that the drug has a short elimination half-life. In individuals with normal kidney function, the half-life is typically very brief, generally ranging from less than one hour to about one hour and a half.


Q: Can Urifast be used for infections other than UTIs?

A: According to the official Indications and Usage section, this medicine is specifically indicated only for the treatment and prevention of urinary tract infections (UTIs) when due to susceptible bacteria. It is not indicated for the treatment of other types of infections.


Q: What should I do if I get diarrhea while taking Urifast?

A: Diarrhea is a common side effect of Urifast. However, official warnings state that if you experience watery or bloody diarrhea, even after the treatment is completed, this situation warrants contacting a healthcare professional immediately, as it could be a sign of a more serious secondary infection.


Q: Can Urifast affect the results of any common lab tests?

A: Official patient information notes that this medicine may interfere with certain laboratory tests, specifically tests that look for glucose (sugar) in the urine. Patients are generally advised to inform any healthcare professional that they are taking this medicine.


Q: Does Urifast help with general bladder pain or inflammation?

A: The drug's primary role is to eliminate the bacterial infection in the urinary tract. While it is not a direct painkiller, the resolution of the underlying infection typically leads to a significant reduction in associated symptoms like bladder pain and inflammation.


Q: Why is hydration important when taking Urifast?

A: Hydration is beneficial because this medicine works best when it achieves and maintains high concentrations in the urine. Staying well-hydrated is also a general part of managing the underlying urinary tract infection.


Q: Can Urifast cause dizziness or affect driving?

A: Official labeling lists dizziness and drowsiness as potential side effects. It is helpful for individuals to be aware of these possible effects before driving or operating heavy machinery.


Q: Is there a maximum time someone can safely take Urifast?

A: Regulatory documents caution that chronic, potentially irreversible side effects, such as lung and liver damage, are typically associated with extended use. This risk is often noted for exposure lasting six months or longer, which is why long-term use requires careful monitoring.


Q: Does Urifast affect sleep patterns?

A: Drowsiness and weakness are reported side effects in official product information. As these are effects on the central nervous system, they may potentially influence or disrupt normal sleep patterns for some individuals.

--UNSURE HOW TO HANDLE THIS LINE BREAK, IT WAS PRESENT IN THE ORIGINAL JSON.

Q: Is there a known risk of developing resistance to Urifast over time?

A: Official sources note that this drug is generally more resilient to the development of bacterial resistance compared to some other antibiotics. However, incomplete or incorrect use of any antimicrobial can still lead to treatment failure.


Q: What is the best time of day to take Urifast?

A: For acute treatment, the medicine is typically taken multiple times a day at evenly spaced intervals. When prescribed for prevention (prophylaxis), it is often recommended as a single dose taken at bedtime.


Q: Does Urifast interact with vitamin supplements?

A: While specific vitamin interactions are not usually listed, the absorption of the drug can be influenced by certain minerals like magnesium. It is recommended that patients share information about all vitamins and supplements they are taking with their healthcare provider.


Q: Is Urifast safe for people with liver conditions?

A: Regulatory warnings state that the medicine can cause liver problems, including liver damage (hepatotoxicity). It is contraindicated in patients with a prior history of liver issues associated with its use, and those with pre-existing conditions require careful monitoring.


Q: What is the typical shelf life of a Urifast prescription?

A: The official shelf life is determined by the manufacturer, often listed as 24 months, when stored under specified conditions. It is important to check the expiration date printed on the packaging, as the medicine should not be used past this date.


Q: Can Urifast cause sensitivity to the sun?

A: While some other antibiotics can increase sun sensitivity (photosensitivity), Urifast is not strongly associated with this side effect based on available regulatory evidence.


Q: Are there generic versions of Urifast available?

A: Yes, the active ingredient in Urifast, which is Nitrofurantoin, is widely available in generic versions. These are often offered in different pharmaceutical formulations, such as capsules or tablets.

How should Urifast be stored and disposed of?

How to Store and Dispose of Urifast

Urifast (nitrofurantoin monohydrate/macrocrystals) must be stored under specific environmental conditions to maintain its labeled stability, as required by regulatory agencies.

Storage Requirements

Condition Requirement
Temperature Controlled Room Temperature: 20 to 25 C (68 to 77 F), with permitted excursions to 30 C.
Protection Protect from excess heat and moisture; store in a cool, dry place.
Packaging Keep the container in which it was dispensed, and ensure it remains tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Urifast must be discarded appropriately to prevent environmental harm. Regulatory instructions prohibit flushing the medicine down the toilet or pouring it down a sink or drain. Dispose of the product according to local guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urifast found in:

A-Z Index: